X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (238) 238
Publication (63) 63
Patent (57) 57
Book Chapter (3) 3
Book / eBook (1) 1
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (91) 91
index medicus (74) 74
life sciences (70) 70
chemistry (57) 57
metallurgy (57) 57
hematology (56) 56
rituximab (52) 52
male (48) 48
female (46) 46
oncology (43) 43
middle aged (41) 41
cancer (40) 40
adult (38) 38
microbiology (38) 38
beer (37) 37
biochemistry (37) 37
compositions or test papers therefor (37) 37
condition-responsive control in microbiological orenzymological processes (37) 37
enzymology (37) 37
measuring or testing processes involving enzymes, nucleicacids or microorganisms (37) 37
mutation or genetic engineering (37) 37
processes of preparing such compositions (37) 37
spirits (37) 37
vinegar (37) 37
wine (37) 37
[sdv.can]life sciences [q-bio]/cancer (35) 35
aged (32) 32
physics (28) 28
hemic and lymphatic diseases (26) 26
investigating or analysing materials by determining theirchemical or physical properties (24) 24
measuring (24) 24
testing (24) 24
anti-cd20 monoclonal-antibody (23) 23
human necessities (23) 23
hygiene (23) 23
medical or veterinary science (23) 23
preparations for medical, dental, or toilet purposes (23) 23
chemotherapy (21) 21
organic chemistry (21) 21
peptides (21) 21
prognosis (21) 21
treatment outcome (21) 21
[ sdv.can ] life sciences [q-bio]/cancer (19) 19
b-cell lymphoma (19) 19
follicular lymphoma (19) 19
immune system diseases (19) 19
non-hodgkins-lymphoma (19) 19
[sdv]life sciences [q-bio] (18) 18
lymphoma (18) 18
lymphomas (18) 18
abridged index medicus (17) 17
antineoplastic agents - therapeutic use (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
chronic lymphocytic-leukemia (17) 17
culture media (17) 17
therapy (17) 17
aged, 80 and over (16) 16
compositions thereof (16) 16
expression (16) 16
lymphoma, follicular - drug therapy (16) 16
microorganisms or enzymes (16) 16
propagating, preserving or maintaining microorganisms (16) 16
trial (15) 15
antibodies, monoclonal, murine-derived (14) 14
disease-free survival (14) 14
fc-gamma-riiia (14) 14
human health and pathology (14) 14
survival (14) 14
antibodies, monoclonal - therapeutic use (13) 13
low-grade (13) 13
patients (13) 13
[ sdv.mhep.hem ] life sciences [q-bio]/human health and pathology/hematology (11) 11
animals (11) 11
care and treatment (11) 11
immunology (11) 11
progression-free survival (11) 11
receptors, igg - genetics (11) 11
retrospective studies (11) 11
follow-up studies (10) 10
leukemia, lymphocytic, chronic, b-cell - drug therapy (10) 10
multiple myeloma (10) 10
polymorphism, genetic (10) 10
[ sdv ] life sciences [q-bio] (9) 9
antibodies, monoclonal - pharmacology (9) 9
antineoplastic agents - administration & dosage (9) 9
antineoplastic agents - pharmacokinetics (9) 9
antineoplastic agents - pharmacology (9) 9
transplantation (9) 9
analysis (8) 8
antibodies, monoclonal - pharmacokinetics (8) 8
antibodies, monoclonal, humanized - administration & dosage (8) 8
c-receptor polymorphisms (8) 8
cyclophosphamide (8) 8
genes (8) 8
genetics (8) 8
leukemia (8) 8
lymphoma, non-hodgkin - drug therapy (8) 8
medicine, research & experimental (8) 8
phase-ii (8) 8
prospective studies (8) 8
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (281) 281
French (38) 38
German (10) 10
Chinese (3) 3
Spanish (2) 2
Danish (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences
Journal Article
Expert review of clinical immunology, 04/2019, Volume 15, Issue 4, p. 383
Rituximab, an anti-CD20 monoclonal antibody (mAb), is indicated in the treatment of B-cell non-Hodgkin lymphomas, chronic lymphoid leukemia, and rheumatoid... 
Journal Article